person · Reporting owner

Huennekens R Scott

Disclosed activity across 9 companies

Tapewire entity: 34767
SEC CIK: 0001365493

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Acutus Medical, Inc.AFIB · Entity 83848	Director	June 15, 2023	June 15, 2023
Envista Holdings CorpNVST · Entity 4007	Director	May 19, 2026	May 21, 2026
Hyperfine, Inc.HYPR · Entity 6865	Director	June 12, 2024	June 12, 2024
NeuroPace IncNPCE · Entity 5459	Director	June 05, 2026	June 05, 2026
QuidelOrtho CorpQDEL · Entity 4986	Director	June 25, 2026	June 29, 2026
REVA Medical, Inc.RVA:AX · Entity 11998	Director	July 09, 2017	July 11, 2017
ViewRay, Inc.VRAY · Entity 111118	Director	June 15, 2020	June 17, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Acutus Medical, Inc.

Report date June 15, 2023 · Filed June 15, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
FORM 4SEC Table I · non-derivative	Direct	21,840	Reported balance After 2023-06-15 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2023-06-15 · Grant · Acquired 10,920 · Balance 21,840 F1: Common Stock F2: Each annual restricted stock unit ("Annual RSU") will be scheduled to vest as to all of the Shares of Common Stock ("Shares) subject to such Annual RSU on the first anniversary of the date of grant of such Annual RSU, if on such date the Reporting Person has remained in continuous service as a director.
FORM 4SEC Table II · derivative / convertible security · Conversion / exercise price $0.83 · Expires 2033-06-15	Direct	25,480	Reported balance After 2023-06-15 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-06-15 · Grant · Acquired 25,480 · Balance 25,480 F4: Stock Options (Right to Buy) F5: Each annual stock option ("the Annual Option") will be scheduled to vest and become exercisable as to all of the Shares subject to such Annual Option on the first anniversary of the date of grant of such Annual Option, fi on such date the Reporting Person has remained in continuous service as director. F1: Common Stock
FORM 4SEC Table I · non-derivative	IndirectBy Front Foot Trust	507,509	Reported balance Holding disclosure · report date 2023-06-15 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 507,509 F1: Common Stock F3: The reporting person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Common Stock

F2: Each annual restricted stock unit ("Annual RSU") will be scheduled to vest as to all of the Shares of Common Stock ("Shares) subject to such Annual RSU on the first anniversary of the date of grant of such Annual RSU, if on such date the Reporting Person has remained in continuous service as a director.

F3: The reporting person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.

F4: Stock Options (Right to Buy)

F5: Each annual stock option ("the Annual Option") will be scheduled to vest and become exercisable as to all of the Shares subject to such Annual Option on the first anniversary of the date of grant of such Annual Option, fi on such date the Reporting Person has remained in continuous service as director.

Envista Holdings Corp

Report date May 19, 2026 · Filed May 21, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	82,105	Reported balance After 2026-05-19 transaction · row 1 1 source row Row 1 · 2026-05-19 · Grant · Acquired 12,585 · Balance 82,105 F1: Consists of an annual equity grant of Restricted Stock Units ("RSUs") for the Reporting Person's service as a director of the Issuer. The RSUs will vest on the first anniversary of the grant date. RSUs are payable in shares of common stock on a one-to-one basis.

Filing footnotes · ownership attribution and instrument terms

F1: Consists of an annual equity grant of Restricted Stock Units ("RSUs") for the Reporting Person's service as a director of the Issuer. The RSUs will vest on the first anniversary of the grant date. RSUs are payable in shares of common stock on a one-to-one basis.

Hyperfine, Inc.

Report date June 12, 2024 · Filed June 12, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.87 · Expires 2034-06-12	Direct	79,200	Reported balance After 2024-06-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-06-12 · Grant · Acquired 79,200 · Balance 79,200 F1: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to Mr. Huennekens' continued service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to Mr. Huennekens' continued service through the applicable vesting date.

NeuroPace Inc

Report date June 05, 2026 · Filed June 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,890	Reported balance After 2026-06-05 transaction · row 1 1 source row Row 1 · 2026-06-05 · Grant · Acquired 2,890 · Balance 2,890 F1: The shares shall vest in twelve (12) equal consecutive monthly installments until all of the shares are fully vested, subject to the Reporting Person's continuous service through each vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.74 · Expires 2036-06-04	Direct	5,368	Reported balance After 2026-06-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-05 · Grant · Acquired 5,368 · Balance 5,368 F2: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable, subject to the Reporting Person's continuous service through each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares shall vest in twelve (12) equal consecutive monthly installments until all of the shares are fully vested, subject to the Reporting Person's continuous service through each vesting date.

F2: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable, subject to the Reporting Person's continuous service through each vesting date.

QuidelOrtho Corp

Report date June 25, 2026 · Filed June 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock Units (Equity Grant)SEC Table II · derivative / convertible security	Direct	15,532	Reported balance After 2026-06-25 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-25 · Grant · Acquired 15,532 · Balance 15,532 F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2: The restricted stock units will vest on June 25, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.

F2: The restricted stock units will vest on June 25, 2027.

REVA Medical, Inc.

Report date July 09, 2017 · Filed July 11, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	27,300	Reported balance After 2017-07-09 transaction · row 1 1 source row Row 1 · 2017-07-09 · Grant · Acquired 6,000 · Balance 27,300 F1: These restricted stock units will vest in full on the earlier of (i) July 9, 2018 or (ii) the day prior to the Issuer's 2018 annual stockholder meeting.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.45 · Expires 2027-07-09	Direct	10,500	Reported balance After 2017-07-09 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-07-09 · Grant · Acquired 10,500 · Balance 10,500 F2: The option shares shall vest in four equal quarterly installments, with the first installment on October 9, 2017.

Filing footnotes · ownership attribution and instrument terms

F1: These restricted stock units will vest in full on the earlier of (i) July 9, 2018 or (ii) the day prior to the Issuer's 2018 annual stockholder meeting.

F2: The option shares shall vest in four equal quarterly installments, with the first installment on October 9, 2017.

ViewRay, Inc.

Report date June 15, 2020 · Filed June 17, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	99,670	Reported balance After 2020-06-15 transaction · row 1 1 source row Row 1 · 2020-06-15 · Grant · Acquired 52,752 · Balance 99,670 F1: The reported securities are RSUs that entitle the Reporting Person to receive one share of Common Stock per RSU upon vesting. All of these RSUs shall vest on June 15, 2021, subject to the Reporting Person remaining a service provider through such date.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities are RSUs that entitle the Reporting Person to receive one share of Common Stock per RSU upon vesting. All of these RSUs shall vest on June 15, 2021, subject to the Reporting Person remaining a service provider through such date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

EndoChoice Holdings, Inc.

Report date November 22, 2016 · Filed November 23, 2016

Section 16 reporting ended · disclosed 2016-11-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common stock, par value $0.001 per shareSEC Table I · non-derivative	IndirectBy Saol Capital LLC	Reported balance After 2016-11-22 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2016-11-22 · Disposition to issuer · Disposed 26,666 · Balance 0 F1: Reporting Person disposed of shares of Issuer Common Stock pursuant to a cash tender offer made by Boston Scientific Corporation as more fully described in the Schedule 14D-9 filed by Issuer with the Securities and Exchange Commission on October 7, 2016, and subsequent amendments thereto (the "Merger"). The Issuer's Board of Directors approved in advance the dispositions by the Reporting Person in the tender offer. F2: Saol Capital LLC is owned equally by The Huennekens Family Trust dated June 14, 2007 and The Kieran and Mary Ellen Gallahue Revocable Family Trust dated January 24, 2004, as amended, which hold voting and dispositive power with respect thereto. The Huennekens Family Trust dated June 14, 2007 is owned directly and equally by the reporting person and Deborah Legome Huennekens. The Kieran and Mary Ellen Gallahue Revocable Trust is owned directly and equally by Kieran Thomas Gallahue and Mary Ellen Gallahue. By virtue of the relationships described in this footnote, the entities and individuals described herein may be deemed to beneficially own the shares owned by Saol Capital.
Common stock, par value $0.001 per shareSEC Table I · non-derivative	IndirectBy Front Foot Trust	Reported balance After 2016-11-22 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2016-11-22 · Disposition to issuer · Disposed 8,423 · Balance 0 F1: Reporting Person disposed of shares of Issuer Common Stock pursuant to a cash tender offer made by Boston Scientific Corporation as more fully described in the Schedule 14D-9 filed by Issuer with the Securities and Exchange Commission on October 7, 2016, and subsequent amendments thereto (the "Merger"). The Issuer's Board of Directors approved in advance the dispositions by the Reporting Person in the tender offer. F3: Shares previously directly held by the reporting person were transferred to Front Foot Trust on September 1, 2016. Front Foot Trust is owned directly and equally by the reporting person and Deborah Legome Huennekens and may therefore be deemed to beneficially own the shares owned by Front Foot Trust.
Common stock, par value $0.001 per shareSEC Table I · non-derivative	Direct	Reported balance After 2016-11-22 transaction · row 3 1 source row Row 3 · 2016-11-22 · Disposition to issuer · Disposed 47,446 · Balance 0 F1: Reporting Person disposed of shares of Issuer Common Stock pursuant to a cash tender offer made by Boston Scientific Corporation as more fully described in the Schedule 14D-9 filed by Issuer with the Securities and Exchange Commission on October 7, 2016, and subsequent amendments thereto (the "Merger"). The Issuer's Board of Directors approved in advance the dispositions by the Reporting Person in the tender offer.

Filing footnotes · ownership attribution and instrument terms

F1: Reporting Person disposed of shares of Issuer Common Stock pursuant to a cash tender offer made by Boston Scientific Corporation as more fully described in the Schedule 14D-9 filed by Issuer with the Securities and Exchange Commission on October 7, 2016, and subsequent amendments thereto (the "Merger"). The Issuer's Board of Directors approved in advance the dispositions by the Reporting Person in the tender offer.

F2: Saol Capital LLC is owned equally by The Huennekens Family Trust dated June 14, 2007 and The Kieran and Mary Ellen Gallahue Revocable Family Trust dated January 24, 2004, as amended, which hold voting and dispositive power with respect thereto. The Huennekens Family Trust dated June 14, 2007 is owned directly and equally by the reporting person and Deborah Legome Huennekens. The Kieran and Mary Ellen Gallahue Revocable Trust is owned directly and equally by Kieran Thomas Gallahue and Mary Ellen Gallahue. By virtue of the relationships described in this footnote, the entities and individuals described herein may be deemed to beneficially own the shares owned by Saol Capital.

F3: Shares previously directly held by the reporting person were transferred to Front Foot Trust on September 1, 2016. Front Foot Trust is owned directly and equally by the reporting person and Deborah Legome Huennekens and may therefore be deemed to beneficially own the shares owned by Front Foot Trust.

NUVASIVE INC

Report date September 01, 2023 · Filed September 05, 2023

Section 16 reporting ended · disclosed 2023-09-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common Stock, par value $0.001 per shareSEC Table I · non-derivative	Direct	Reported balance After 2023-09-01 transaction · row 1 1 source row Row 1 · 2023-09-01 · Disposition to issuer · Disposed 1,360 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger (the "Effective Time"), each share of the Issuer's common stock issued and outstanding immediately prior to the Effective Time (other than certain excluded shares) was cancelled and converted into the right to receive 0.75 shares of Class A common stock of Globus ("Globus Class A Common Stock"), par value $0.001 per share (the "Exchange Ratio" and such shares, the "Merger Consideration"), and cash in lieu of fractional shares.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-09-01 · Disposition to issuer · Disposed 2,577 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-09-01 · Disposition to issuer · Disposed 3,095 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-09-01 · Disposition to issuer · Disposed 2,702 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-09-01 · Disposition to issuer · Disposed 3,788 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-09-01 · Disposition to issuer · Disposed 4,816 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger (the "Effective Time"), each share of the Issuer's common stock issued and outstanding immediately prior to the Effective Time (other than certain excluded shares) was cancelled and converted into the right to receive 0.75 shares of Class A common stock of Globus ("Globus Class A Common Stock"), par value $0.001 per share (the "Exchange Ratio" and such shares, the "Merger Consideration"), and cash in lieu of fractional shares.

F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting.

F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 25, 2026 Filed Jun 29, 2026 22:00 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantRestricted Stock Units (Equity Grant) · Derivative	15,532	$0.00	$0.00	Disclosure SEC source: 0001365493-26-000008 · wk-form4_1782770440.xml · derivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,532 Underlying: Common Stock · 15,532 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units will vest on June 25, 2027. F2 · derivative.expiration_date: The restricted stock units will vest on June 25, 2027. Read SEC document
June 05, 2026 Filed Jun 5, 2026 21:13 UTC	NeuroPace Inc NPCE · Entity 5459	GrantStock Option (Right to Buy) · Derivative	5,368	$0.00 Strike: $15.74	$0.00	Disclosure SEC source: 0001628280-26-041324 · wk-form4_1780694002.xml · derivative · entry 2 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,368 Underlying: Common Stock · 5,368 shares Expires 2036-06-04 F2 · derivative.exercise_date: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable, subject to the Reporting Person's continuous service through each vesting date. Read SEC document
June 05, 2026 Filed Jun 5, 2026 21:13 UTC	NeuroPace Inc NPCE · Entity 5459	GrantCommon Stock	2,890	$0.00	$0.00	Disclosure SEC source: 0001628280-26-041324 · wk-form4_1780694002.xml · nonDerivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,890 F1 · shares: The shares shall vest in twelve (12) equal consecutive monthly installments until all of the shares are fully vested, subject to the Reporting Person's continuous service through each vesting date. Read SEC document
May 29, 2026 Filed Jun 2, 2026 20:08 UTC	QuidelOrtho Corp QDEL · Entity 4986	Exercise / conversionRestricted Stock Units (Equity Grant) · Derivative	6,829	$0.00	$0.00	Disclosure SEC source: 0001365493-26-000005 · wk-form4_1780430930.xml · derivative · entry 2 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,829 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: The restricted stock units vested on May 29, 2026. F3 · derivative.expiration_date: The restricted stock units vested on May 29, 2026. Read SEC document
May 29, 2026 Filed Jun 2, 2026 20:08 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantCommon Stock	6,829	$0.00	$0.00	Disclosure SEC source: 0001365493-26-000005 · wk-form4_1780430930.xml · nonDerivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,352 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document
May 19, 2026 Filed May 21, 2026 20:36 UTC	Envista Holdings Corp NVST · Entity 4007	GrantCommon Stock	12,585	$0.00	$0.00	Disclosure SEC source: 0001365493-26-000003 · wk-form4_1779395802.xml · nonDerivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,105 F1 · shares: Consists of an annual equity grant of Restricted Stock Units ("RSUs") for the Reporting Person's service as a director of the Issuer. The RSUs will vest on the first anniversary of the grant date. RSUs are payable in shares of common stock on a one-to-one basis. Read SEC document
June 10, 2025 Filed Jun 12, 2025 20:54 UTC	Envista Holdings Corp NVST · Entity 4007	GrantCommon Stock	14,370	$0.00	$0.00	Disclosure SEC source: 0001628280-25-031060 · wk-form4_1749761687.xml · nonDerivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,520 F1 · shares: Consists of an annual equity grant of Restricted Stock Units ("RSUs") for the Reporting Person's service as a director of the Issuer. The RSUs will vest on the first anniversary of the grant date. RSUs are payable in shares of common stock on a one-to-one basis. Read SEC document
June 06, 2025 Filed Jun 9, 2025 21:26 UTC	NeuroPace Inc NPCE · Entity 5459	GrantStock Option (right to buy) · Derivative	8,745	$0.00 Strike: $13.15	$0.00	Disclosure SEC source: 0001415889-25-016327 · form4-06092025_050608.xml · derivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,745 Underlying: Common Stock · 8,745 shares Expires 2035-06-05 F1 · derivative.exercise_date: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable, subject to the Reporting Person's continuous service through each vesting date. Read SEC document
May 29, 2025 Filed Jun 2, 2025 20:23 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantRestricted Stock Units (Equity Grant) · Derivative	6,829	$0.00	$0.00	Disclosure SEC source: 0001906324-25-000127 · wk-form4_1748895794.xml · derivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,829 Underlying: Common Stock · 6,829 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units will vest on May 29, 2026. F2 · derivative.expiration_date: The restricted stock units will vest on May 29, 2026. Read SEC document
May 22, 2025 Filed May 27, 2025 20:21 UTC	QuidelOrtho Corp QDEL · Entity 4986	Exercise / conversionRestricted Stock Units (Equity Grant) · Derivative	2,523	$0.00	$0.00	Disclosure SEC source: 0001906324-25-000095 · wk-form4_1748377266.xml · derivative · entry 2 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,523 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: The restricted stock units vested on May 22, 2025. F3 · derivative.expiration_date: The restricted stock units vested on May 22, 2025. Read SEC document
May 22, 2025 Filed May 27, 2025 20:21 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantCommon Stock	2,523	$0.00	$0.00	Disclosure SEC source: 0001906324-25-000095 · wk-form4_1748377266.xml · nonDerivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,523 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 3. Read SEC document
January 06, 2025 Filed Jan 8, 2025 21:57 UTC	NeuroPace Inc NPCE · Entity 5459	GrantStock Option (Right to Buy) · Derivative	15,507	$0.00 Strike: $11.93	$0.00	Disclosure SEC source: 0001415889-25-001147 · form4-01082025_090108.xml · derivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,507 Underlying: Common Stock · 15,507 shares Expires 2035-01-05 F1 · derivative.exercise_date: The shares subject to the option shall vest in thirty six (36) equal consecutive monthly installments until all of the option shares are fully vested and exercisable. Read SEC document
June 12, 2024 Filed Jun 12, 2024 21:02 UTC	Hyperfine, Inc. HYPR · Entity 6865	GrantStock Options (right to buy) · Derivative	79,200	$0.00 Strike: $0.87	$0.00	Disclosure SEC source: 0001209191-24-005848 · doc4.xml · derivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,200 Underlying: Class A Common Stock · 79,200 shares Expires 2034-06-12 F1 · derivative.exercise_date: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to Mr. Huennekens' continued service through the applicable vesting date. Read SEC document
May 21, 2024 Filed May 23, 2024 20:33 UTC	Envista Holdings Corp NVST · Entity 4007	GrantCommon Stock	14,170	$0.00	$0.00	Disclosure SEC source: 0001757073-24-000051 · wk-form4_1716496365.xml · nonDerivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,150 F1 · shares: Consists of an annual equity grant of Restricted Stock Units ("RSUs") for the Reporting Person's service as a director of the Issuer. The RSUs will vest one year after the grant date. RSUs are payable in shares of common stock on a one-to-one basis. Read SEC document
September 01, 2023 Filed Sep 5, 2023 16:52 UTC	NUVASIVE INC NUVA · Entity 110002	Disposition to issuerRestricted Stock Unit · Derivative	4,816	$0.00	$0.00	Disclosure SEC source: 0001209191-23-048184 · doc4.xml · derivative · entry 6 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,816 shares Expires not disclosed F3 · derivative.exercise_price: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. Read SEC document
September 01, 2023 Filed Sep 5, 2023 16:52 UTC	NUVASIVE INC NUVA · Entity 110002	Disposition to issuerRestricted Stock Unit · Derivative	3,788	$0.00	$0.00	Disclosure SEC source: 0001209191-23-048184 · doc4.xml · derivative · entry 5 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,788 shares Expires not disclosed F2 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. Read SEC document
September 01, 2023 Filed Sep 5, 2023 16:52 UTC	NUVASIVE INC NUVA · Entity 110002	Disposition to issuerRestricted Stock Unit · Derivative	2,702	$0.00	$0.00	Disclosure SEC source: 0001209191-23-048184 · doc4.xml · derivative · entry 4 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,702 shares Expires not disclosed F2 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. Read SEC document
September 01, 2023 Filed Sep 5, 2023 16:52 UTC	NUVASIVE INC NUVA · Entity 110002	Disposition to issuerRestricted Stock Unit · Derivative	3,095	$0.00	$0.00	Disclosure SEC source: 0001209191-23-048184 · doc4.xml · derivative · entry 3 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,095 shares Expires not disclosed F2 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. Read SEC document
September 01, 2023 Filed Sep 5, 2023 16:52 UTC	NUVASIVE INC NUVA · Entity 110002	Disposition to issuerRestricted Stock Unit · Derivative	2,577	$0.00	$0.00	Disclosure SEC source: 0001209191-23-048184 · doc4.xml · derivative · entry 2 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,577 shares Expires not disclosed F2 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. Read SEC document
September 01, 2023 Filed Sep 5, 2023 16:52 UTC	NUVASIVE INC NUVA · Entity 110002	Disposition to issuerCommon Stock, par value $0.001 per share	1,360	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-048184 · doc4.xml · nonDerivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger (the "Effective Time"), each share of the Issuer's common stock issued and outstanding immediately prior to the Effective Time (other than certain excluded shares) was cancelled and converted into the right to receive 0.75 shares of Class A common stock of Globus ("Globus Class A Common Stock"), par value $0.001 per share (the "Exchange Ratio" and such shares, the "Merger Consideration"), and cash in lieu of fractional shares. Read SEC document
June 15, 2023 Filed Jun 15, 2023 22:07 UTC	Acutus Medical, Inc. AFIB · Entity 83848	GrantFORM 4 · Derivative	25,480	$0.00 Strike: $0.83	$0.00	Disclosure SEC source: 0001628280-23-022326 · wf-form4_168686682476075.xml · derivative · entry 3 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,480 Underlying: FORM 4 · 25,480 shares Expires 2033-06-15 F4 · security: Stock Options (Right to Buy) F5 · derivative.exercise_date: Each annual stock option ("the Annual Option") will be scheduled to vest and become exercisable as to all of the Shares subject to such Annual Option on the first anniversary of the date of grant of such Annual Option, fi on such date the Reporting Person has remained in continuous service as director. F1 · derivative.underlying: Common Stock Read SEC document
June 15, 2023 Filed Jun 15, 2023 22:07 UTC	Acutus Medical, Inc. AFIB · Entity 83848	GrantFORM 4	10,920	$0.00	$0.00	Disclosure SEC source: 0001628280-23-022326 · wf-form4_168686682476075.xml · nonDerivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,840 F1 · security: Common Stock F2 · shares: Each annual restricted stock unit ("Annual RSU") will be scheduled to vest as to all of the Shares of Common Stock ("Shares) subject to such Annual RSU on the first anniversary of the date of grant of such Annual RSU, if on such date the Reporting Person has remained in continuous service as a director. Read SEC document
June 09, 2023 Filed Jun 12, 2023 17:52 UTC	NUVASIVE INC NUVA · Entity 110002	GrantRSUs · Derivative	4,816	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-23-036453 · doc4.xml · derivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,816 Underlying: Common Stock · 4,816 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2024 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. F3 · derivative.exercise_date: On February 8, 2023, Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Globus Medical, Inc. ("Globus Medical") and Zebra Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Globus Medical. The Merger Agreement provides, among other things, that subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will merge with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Globus Medical. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each RSU outstanding immediately prior to the Effective Time held by the Reporting Person will fully vest and be cancelled and converted automatically into the right to receive (without interest) 0.75 fully paid and non-assessable shares of Class A common stock of Globus Medical (and cash in lieu of any fractional shares) in respect of each share of Issuer's common stock underlying such RSU. F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2024 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. F3 · derivative.expiration_date: On February 8, 2023, Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Globus Medical, Inc. ("Globus Medical") and Zebra Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Globus Medical. The Merger Agreement provides, among other things, that subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will merge with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Globus Medical. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each RSU outstanding immediately prior to the Effective Time held by the Reporting Person will fully vest and be cancelled and converted automatically into the right to receive (without interest) 0.75 fully paid and non-assessable shares of Class A common stock of Globus Medical (and cash in lieu of any fractional shares) in respect of each share of Issuer's common stock underlying such RSU. Read SEC document
June 09, 2023 Filed Jun 12, 2023 20:30 UTC	Hyperfine, Inc. HYPR · Entity 6865	GrantStock Option (right to buy) · Derivative	237,437	$0.00 Strike: $1.97	$0.00	Disclosure SEC source: 0001209191-23-036328 · doc4.xml · derivative · entry 3 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,437 Underlying: Class A Common Stock · 237,437 shares Expires 2033-06-09 F4 · derivative.exercise_date: The shares underlying this option vest 100% on June 9, 2028, subject to Mr. Huennekens' continued service through the vesting date. Read SEC document
June 09, 2023 Filed Jun 12, 2023 20:30 UTC	Hyperfine, Inc. HYPR · Entity 6865	Disposition to issuerStock Options (right to buy) · Derivative	237,437	$0.00 Strike: $0.91	$0.00	Disclosure SEC source: 0001209191-23-036328 · doc4.xml · derivative · entry 2 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 237,437 shares Expires 2031-04-27 F3 · price: On June 9, 2023, Mr. Huennekens was granted a new stock option to purchase 237,437 shares of the Issuer's Class A common stock reported below that was contingent upon the cancellation of this stock option. F2 · derivative.exercise_date: The shares underlying this option vest and will become exercisable upon the first to occur of the following: (1) the completion of a SPAC transaction within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share of $30.00 or more for at least 20 out of 30 consecutive trading days within four years of the closing of the SPAC transaction; (2) the completion of an IPO within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share that equals or exceeds 3.0 times $3.92 (as adjusted) within four years of the closing of the IPO; or (3) the closing of a private financing round within four years of Mr. Huennekens' start date in which $50 million or more is raised and Hyperfine's stock price per share equals or exceeds 3.0 times $3.92 (as adjusted). Read SEC document
June 09, 2023 Filed Jun 12, 2023 20:30 UTC	Hyperfine, Inc. HYPR · Entity 6865	GrantStock Options (right to buy) · Derivative	112,000	$0.00 Strike: $1.97	$0.00	Disclosure SEC source: 0001209191-23-036328 · doc4.xml · derivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,000 Underlying: Class A Common Stock · 112,000 shares Expires 2033-06-09 F1 · derivative.exercise_date: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to Mr. Huennekens' continued service through the applicable vesting date. Read SEC document
May 23, 2023 Filed May 25, 2023 20:34 UTC	Envista Holdings Corp NVST · Entity 4007	GrantCommon Stock	7,625	$0.00	$0.00	Disclosure SEC source: 0001757073-23-000044 · wf-form4_168504684010744.xml · nonDerivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,980 F1 · shares: Consists of an annual equity grant of Restricted Stock Units ("RSUs") for the Reporting Person's service as a director of the Issuer. The RSUs will vest one year after the grant date. RSUs are payable in sharesof common stock on a one-to-one basis. Read SEC document
October 31, 2022 Filed Nov 1, 2022 21:53 UTC	Hyperfine, Inc. HYPR · Entity 6865	GrantStock Option (right to buy) · Derivative	237,437	Not disclosed Strike: $0.91	Not disclosed	Disclosure SEC source: 0001209191-22-055106 · doc4.xml · derivative · entry 8 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,437 Underlying: Class A Common Stock · 237,437 shares Expires 2031-04-27 F4 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on December 22, 2021. F4 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on December 22, 2021. F5 · price: The shares underlying this option vest and will become exercisable upon the first to occur of the following: (1) the completion of a SPAC transaction within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share of $30.00 or more for at least 20 out of 30 consecutive trading days within four years of the closing of the SPAC transaction; (2) the completion of an IPO within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share that equals or exceeds 3.0 times $3.92 (as adjusted) within four years of the closing of the IPO; or (3) the closing of a private financing round within four years of Mr. Huennekens' start date in which $50 million or more is raised and Hyperfine's stock price per share equals or exceeds 3.0 times $3.92 (as adjusted). F5 · derivative.exercise_date: The shares underlying this option vest and will become exercisable upon the first to occur of the following: (1) the completion of a SPAC transaction within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share of $30.00 or more for at least 20 out of 30 consecutive trading days within four years of the closing of the SPAC transaction; (2) the completion of an IPO within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share that equals or exceeds 3.0 times $3.92 (as adjusted) within four years of the closing of the IPO; or (3) the closing of a private financing round within four years of Mr. Huennekens' start date in which $50 million or more is raised and Hyperfine's stock price per share equals or exceeds 3.0 times $3.92 (as adjusted). Read SEC document
October 31, 2022 Filed Nov 1, 2022 21:53 UTC	Hyperfine, Inc. HYPR · Entity 6865	Disposition to issuerStock Option (right to buy) · Derivative	237,437	Not disclosed Strike: $3.27	Not disclosed	Disclosure SEC source: 0001209191-22-055106 · doc4.xml · derivative · entry 7 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 237,437 shares Expires 2031-04-27 F4 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on December 22, 2021. F4 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on December 22, 2021. F5 · price: The shares underlying this option vest and will become exercisable upon the first to occur of the following: (1) the completion of a SPAC transaction within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share of $30.00 or more for at least 20 out of 30 consecutive trading days within four years of the closing of the SPAC transaction; (2) the completion of an IPO within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share that equals or exceeds 3.0 times $3.92 (as adjusted) within four years of the closing of the IPO; or (3) the closing of a private financing round within four years of Mr. Huennekens' start date in which $50 million or more is raised and Hyperfine's stock price per share equals or exceeds 3.0 times $3.92 (as adjusted). F5 · derivative.exercise_date: The shares underlying this option vest and will become exercisable upon the first to occur of the following: (1) the completion of a SPAC transaction within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share of $30.00 or more for at least 20 out of 30 consecutive trading days within four years of the closing of the SPAC transaction; (2) the completion of an IPO within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share that equals or exceeds 3.0 times $3.92 (as adjusted) within four years of the closing of the IPO; or (3) the closing of a private financing round within four years of Mr. Huennekens' start date in which $50 million or more is raised and Hyperfine's stock price per share equals or exceeds 3.0 times $3.92 (as adjusted). Read SEC document
October 31, 2022 Filed Nov 1, 2022 21:53 UTC	Hyperfine, Inc. HYPR · Entity 6865	GrantStock Option (right to buy) · Derivative	237,437	Not disclosed Strike: $0.91	Not disclosed	Disclosure SEC source: 0001209191-22-055106 · doc4.xml · derivative · entry 6 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,437 Underlying: Class A Common Stock · 237,437 shares Expires 2031-04-27 F3 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on December 22, 2021. The shares underlying this option vest and will become exercisable upon the first to occur of the following: (1) the completion of a business combination that results in the operating business of Hyperfine and Liminal becoming a publicly traded company (a "SPAC transaction") within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share of $15.00 or more for at least 20 out of 30 consecutive trading days within three years of the closing of the SPAC transaction; (2) the completion of the initial public offering of Hyperfine and Liminal ("IPO") within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share that equals or exceeds 1.5 times $3.92 as adjusted. F3 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on December 22, 2021. The shares underlying this option vest and will become exercisable upon the first to occur of the following: (1) the completion of a business combination that results in the operating business of Hyperfine and Liminal becoming a publicly traded company (a "SPAC transaction") within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share of $15.00 or more for at least 20 out of 30 consecutive trading days within three years of the closing of the SPAC transaction; (2) the completion of the initial public offering of Hyperfine and Liminal ("IPO") within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share that equals or exceeds 1.5 times $3.92 as adjusted. F3 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on December 22, 2021. The shares underlying this option vest and will become exercisable upon the first to occur of the following: (1) the completion of a business combination that results in the operating business of Hyperfine and Liminal becoming a publicly traded company (a "SPAC transaction") within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share of $15.00 or more for at least 20 out of 30 consecutive trading days within three years of the closing of the SPAC transaction; (2) the completion of the initial public offering of Hyperfine and Liminal ("IPO") within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share that equals or exceeds 1.5 times $3.92 as adjusted. Read SEC document
October 31, 2022 Filed Nov 1, 2022 21:53 UTC	Hyperfine, Inc. HYPR · Entity 6865	Disposition to issuerStock Option (right to buy) · Derivative	237,437	Not disclosed Strike: $3.27	Not disclosed	Disclosure SEC source: 0001209191-22-055106 · doc4.xml · derivative · entry 5 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 237,437 shares Expires 2031-04-27 F3 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on December 22, 2021. The shares underlying this option vest and will become exercisable upon the first to occur of the following: (1) the completion of a business combination that results in the operating business of Hyperfine and Liminal becoming a publicly traded company (a "SPAC transaction") within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share of $15.00 or more for at least 20 out of 30 consecutive trading days within three years of the closing of the SPAC transaction; (2) the completion of the initial public offering of Hyperfine and Liminal ("IPO") within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share that equals or exceeds 1.5 times $3.92 as adjusted. F3 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on December 22, 2021. The shares underlying this option vest and will become exercisable upon the first to occur of the following: (1) the completion of a business combination that results in the operating business of Hyperfine and Liminal becoming a publicly traded company (a "SPAC transaction") within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share of $15.00 or more for at least 20 out of 30 consecutive trading days within three years of the closing of the SPAC transaction; (2) the completion of the initial public offering of Hyperfine and Liminal ("IPO") within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share that equals or exceeds 1.5 times $3.92 as adjusted. F3 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on December 22, 2021. The shares underlying this option vest and will become exercisable upon the first to occur of the following: (1) the completion of a business combination that results in the operating business of Hyperfine and Liminal becoming a publicly traded company (a "SPAC transaction") within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share of $15.00 or more for at least 20 out of 30 consecutive trading days within three years of the closing of the SPAC transaction; (2) the completion of the initial public offering of Hyperfine and Liminal ("IPO") within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share that equals or exceeds 1.5 times $3.92 as adjusted. Read SEC document
October 31, 2022 Filed Nov 1, 2022 21:53 UTC	Hyperfine, Inc. HYPR · Entity 6865	GrantStock Option (right to buy) · Derivative	712,312	Not disclosed Strike: $0.91	Not disclosed	Disclosure SEC source: 0001209191-22-055106 · doc4.xml · derivative · entry 4 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 712,312 Underlying: Class A Common Stock · 712,312 shares Expires 2031-04-27 F2 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on December 22, 2021, of which 222,595 shares vested and the remainder of the options vesting in equal monthly installments, subject to Mr. Huennekens' continued service on each vesting date. F2 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on December 22, 2021, of which 222,595 shares vested and the remainder of the options vesting in equal monthly installments, subject to Mr. Huennekens' continued service on each vesting date. F2 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on December 22, 2021, of which 222,595 shares vested and the remainder of the options vesting in equal monthly installments, subject to Mr. Huennekens' continued service on each vesting date. Read SEC document
October 31, 2022 Filed Nov 1, 2022 21:53 UTC	Hyperfine, Inc. HYPR · Entity 6865	Disposition to issuerStock Option (right to buy) · Derivative	712,312	Not disclosed Strike: $3.27	Not disclosed	Disclosure SEC source: 0001209191-22-055106 · doc4.xml · derivative · entry 3 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 712,312 shares Expires 2031-04-27 F2 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on December 22, 2021, of which 222,595 shares vested and the remainder of the options vesting in equal monthly installments, subject to Mr. Huennekens' continued service on each vesting date. F2 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on December 22, 2021, of which 222,595 shares vested and the remainder of the options vesting in equal monthly installments, subject to Mr. Huennekens' continued service on each vesting date. F2 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on December 22, 2021, of which 222,595 shares vested and the remainder of the options vesting in equal monthly installments, subject to Mr. Huennekens' continued service on each vesting date. Read SEC document
October 31, 2022 Filed Nov 1, 2022 21:53 UTC	Hyperfine, Inc. HYPR · Entity 6865	GrantStock Option (right to buy) · Derivative	237,437	Not disclosed Strike: $0.91	Not disclosed	Disclosure SEC source: 0001209191-22-055106 · doc4.xml · derivative · entry 2 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,437 Underlying: Class A Common Stock · 237,437 shares Expires 2032-03-29 F1 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 29, 2022. The shares underlying this option vest in full on March 29, 2027, subject to Mr. Huenneken's continued service through the vesting date. F1 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 29, 2022. The shares underlying this option vest in full on March 29, 2027, subject to Mr. Huenneken's continued service through the vesting date. F1 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 29, 2022. The shares underlying this option vest in full on March 29, 2027, subject to Mr. Huenneken's continued service through the vesting date. Read SEC document
October 31, 2022 Filed Nov 1, 2022 21:53 UTC	Hyperfine, Inc. HYPR · Entity 6865	Disposition to issuerStock Option (right to buy) · Derivative	237,437	Not disclosed Strike: $3.32	Not disclosed	Disclosure SEC source: 0001209191-22-055106 · doc4.xml · derivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 237,437 shares Expires 2032-03-29 F1 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 29, 2022. The shares underlying this option vest in full on March 29, 2027, subject to Mr. Huenneken's continued service through the vesting date. F1 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 29, 2022. The shares underlying this option vest in full on March 29, 2027, subject to Mr. Huenneken's continued service through the vesting date. F1 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 29, 2022. The shares underlying this option vest in full on March 29, 2027, subject to Mr. Huenneken's continued service through the vesting date. Read SEC document
October 01, 2022 Filed Oct 11, 2022 21:01 UTC	Acutus Medical, Inc. AFIB · Entity 83848	GrantStock Options (Right to Buy) · Derivative	5,880	$0.00 Strike: $0.88	$0.00	Disclosure SEC source: 0000950103-22-017614 · dp182284_4-huennekens.xml · derivative · entry 3 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,880 Underlying: Common Stock · 5,880 shares Expires 2032-10-01 F3 · derivative.exercise_date: Each annual stock option (the "Annual Option") will be scheduled to vest and become exercisable as to all of the Shares subject to such Annual Option on the first anniversary of the date of grant of such Annual Option, if on such date the Reporting Person has remained in continuous service as a director. Read SEC document
October 01, 2022 Filed Oct 11, 2022 21:01 UTC	Acutus Medical, Inc. AFIB · Entity 83848	GrantCommon Stock	2,520	$0.00	$0.00	Disclosure SEC source: 0000950103-22-017614 · dp182284_4-huennekens.xml · nonDerivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,920 F1 · shares: Each annual restricted stock unit ("Annual RSU") will be scheduled to vest as to all of the shares of Common Stock ("Shares") subject to such Annual RSU on the first anniversary of the date of grant of such Annual RSU, if on such date the Reporting Person has remained in continuous service as a director. Read SEC document
June 16, 2022 Filed Jun 21, 2022 21:43 UTC	Acutus Medical, Inc. AFIB · Entity 83848	GrantStock Options (Right to Buy) · Derivative	19,600	$0.00 Strike: $0.50	$0.00	Disclosure SEC source: 0000950103-22-010954 · dp175622_4-huennekens.xml · derivative · entry 3 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,600 Underlying: Common Stock · 19,600 shares Expires 2032-06-16 F3 · derivative.exercise_date: Each annual stock option (the "Annual Option") will be scheduled to vest and become exercisable as to all of the Shares subject to such Annual Option on the first anniversary of the date of grant of such Annual Option, if on such date the Reporting Person has remained in continuous service as a director. Read SEC document
June 16, 2022 Filed Jun 21, 2022 21:43 UTC	Acutus Medical, Inc. AFIB · Entity 83848	GrantCommon Stock	8,400	$0.00	$0.00	Disclosure SEC source: 0000950103-22-010954 · dp175622_4-huennekens.xml · nonDerivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,400 F1 · shares: Each annual restricted stock unit ("Annual RSU") will be scheduled to vest as to all of the shares of Common Stock ("Shares") subject to such Annual RSU on the first anniversary of the date of grant of such Annual RSU, if on such date the Reporting Person has remained in continuous service as a director. Read SEC document
June 09, 2022 Filed Jun 13, 2022 20:08 UTC	Hyperfine, Inc. HYPR · Entity 6865	GrantStock Options (right to buy) · Derivative	85,345	$0.00 Strike: $2.20	$0.00	Disclosure SEC source: 0001209191-22-036275 · doc4.xml · derivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,345 Underlying: Class A Common Stock · 85,345 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to Mr. Huenneken's continued service through the applicable vesting date. Read SEC document
June 03, 2022 Filed Jun 3, 2022 23:35 UTC	Acutus Medical, Inc. AFIB · Entity 83848	SaleCommon Stock	60,000	$0.58	$34,800.00	Disclosure SEC source: 0000950103-22-010124 · dp174786_4-huennekens.xml · nonDerivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Front Foot Trust Disclosed balance after: 507,509 F1 · shares: These securities were transferred by the reporting person to Front Foot Trust on March 10, 2022. The reporting person and Deborah Legome Huennekens are co-trustees of Front Foot Trust. F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $0.5800 to $0.6215 inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of securities sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: The reporting person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
May 24, 2022 Filed May 31, 2022 20:33 UTC	Envista Holdings Corp NVST · Entity 4007	GrantCommon Stock	5,930	$0.00	$0.00	Disclosure SEC source: 0001757073-22-000078 · wf-form4_165402916949843.xml · nonDerivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,355 F1 · shares: Consists of an annual equity grant of Restricted Stock Units ("RSUs") for the Reporting Person's service as a director of the Issuer. The RSUs will vest one year after the grant date. RSUs are payable in sharesof common stock on a one-to-one basis. Read SEC document
May 11, 2022 Filed May 13, 2022 17:52 UTC	NUVASIVE INC NUVA · Entity 110002	GrantRSUs · Derivative	3,788	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-22-028938 · doc4.xml · derivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,788 Underlying: Common Stock · 3,788 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2023 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2023 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. Read SEC document
March 29, 2022 Filed Mar 31, 2022 22:09 UTC	Hyperfine, Inc. HYPR · Entity 6865	GrantStock Option (right to buy) · Derivative	237,437	$0.00 Strike: $3.32	$0.00	Disclosure SEC source: 0001104659-22-041203 · tm2211004-6_4seq1.xml · derivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,437 Underlying: Class A Common Stock · 237,437 shares Expires 2032-03-29 F1 · derivative.exercise_date: The shares underlying this option vest in full on March 29, 2027, subject to Mr. Huenneken's continued service through the vesting date. Read SEC document
December 23, 2021 Filed Dec 24, 2021 02:42 UTC	Hyperfine, Inc. HYPR · Entity 6865	GrantClass A Common Stock	16,483	$0.00	$0.00	Disclosure SEC source: 0001104659-21-153332 · tm2135698-15_4seq1.xml · nonDerivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,483 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal annual installments over three years beginning on December 23, 2022, subject to Mr. Huennekens' continued service through the applicable vesting date. Read SEC document
December 23, 2021 Filed Jan 11, 2022 02:41 UTC Amendment	Hyperfine, Inc. HYPR · Entity 6865	GrantClass A Common Stock	19,586	$0.00	$0.00	Disclosure SEC source: 0001104659-22-002889 · tm222483-4_4aseq1.xml · nonDerivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,586 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal annual installments over three years beginning on December 23, 2022, subject to Mr. Huennekens' continued service through the applicable vesting date. Read SEC document
December 22, 2021 Filed Dec 24, 2021 02:42 UTC	Hyperfine, Inc. HYPR · Entity 6865	GrantStock Option (right to buy) · Derivative	237,437	Not disclosed Strike: $3.27	Not disclosed	Disclosure SEC source: 0001104659-21-153332 · tm2135698-15_4seq1.xml · derivative · entry 4 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,437 Underlying: Class A Common Stock · 237,437 shares Expires 2031-04-27 F9 · price: Received in connection with the Mergers in exchange for a stock option to acquire 725,000 shares of Hyperfine common stock for $1.07 per share. F8 · derivative.exercise_date: The shares underlying this option vest and will become exercisable upon the first to occur of the following: (1) the completion of a SPAC transaction within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share of $30.00 or more for at least 20 out of 30 consecutive trading days within four years of the closing of the SPAC transaction; (2) the completion of an IPO within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share that equals or exceeds 3.0 times $3.92 (as adjusted) within four years of the closing of the IPO; or (3) the closing of a private financing round within four years of Mr. Huennekens' start date in which $50 million or more is raised and Hyperfine's stock price per share equals or exceeds 3.0 times $3.92 (as adjusted). Read SEC document
December 22, 2021 Filed Dec 24, 2021 02:42 UTC	Hyperfine, Inc. HYPR · Entity 6865	GrantStock Option (right to buy) · Derivative	237,437	Not disclosed Strike: $3.27	Not disclosed	Disclosure SEC source: 0001104659-21-153332 · tm2135698-15_4seq1.xml · derivative · entry 3 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,437 Underlying: Class A Common Stock · 237,437 shares Expires 2031-04-27 F7 · price: Received in connection with the Mergers in exchange for a stock option to acquire 725,000 shares of Hyperfine common stock for $1.07 per share. F5 · derivative.exercise_date: The shares underlying this option vest and will become exercisable upon the first to occur of the following: (1) the completion of a business combination that results in the operating business of Hyperfine and Liminal becoming a publicly traded company (a "SPAC transaction") within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share of $15.00 or more for at least 20 out of 30 consecutive trading days within three years of the closing of the SPAC transaction; (2) the completion of the initial public offering of Hyperfine and Liminal ("IPO") F6 · derivative.exercise_date: within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share that equals or exceeds 1.5 times $3.92 (as adjusted) within three years of the closing of the IPO; or (3) the closing of a private financing round within three years of Mr. Huennekens' start date in which $50 million or more is raised and Hyperfine's stock price per share equals or exceeds 1.5 times $3.92 (as adjusted). Read SEC document
December 22, 2021 Filed Dec 24, 2021 02:42 UTC	Hyperfine, Inc. HYPR · Entity 6865	GrantStock Option (right to buy) · Derivative	712,312	Not disclosed Strike: $3.27	Not disclosed	Disclosure SEC source: 0001104659-21-153332 · tm2135698-15_4seq1.xml · derivative · entry 2 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 712,312 Underlying: Class A Common Stock · 712,312 shares Expires 2031-04-27 F3 · price: In connection with the closing of the transactions contemplated by the Business Combination Agreement, dated as of July 7, 2021, by and among HealthCor Catalio Acquisition Corp. ("HealthCor"), Optimus Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub I"), Optimus Merger Sub II, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub II"), Hyperfine, Inc., a Delaware corporation ("Hyperfine"), and Liminal Sciences, Inc., a Delaware corporation ("Liminal"), F4 · price: pursuant to which Merger Sub I merged with and into Hyperfine (the "Hyperfine Merger"), with Hyperfine surviving the Hyperfine Merger as a wholly owned subsidiary of HealthCor, and Merger Sub II merged with and into Liminal (the "Liminal Merger" and, together with the Hyperfine Merger, the "Mergers"), with Liminal surviving the Liminal Merger as a wholly owned subsidiary of HealthCor (which changed its name to "Hyperfine, Inc.", the "Issuer"), these shares were received in connection with the Mergers in exchange for a stock option to acquire 2,175,000 shares of Hyperfine common stock for $1.07 per share. F2 · derivative.exercise_date: The shares underlying this option vest as to 25% on June 30, 2022, with the remainder of the options vesting in equal monthly installments over the following 36 months, subject to Mr. Huennekens' continued service on each vesting date. Read SEC document
December 22, 2021 Filed Jan 11, 2022 02:41 UTC Amendment	Hyperfine, Inc. HYPR · Entity 6865	GrantStock Option (right to buy) · Derivative	237,437	Not disclosed Strike: $3.27	Not disclosed	Disclosure SEC source: 0001104659-22-002889 · tm222483-4_4aseq1.xml · derivative · entry 4 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,437 Underlying: Class A Common Stock · 237,437 shares Expires 2031-04-27 F9 · price: Received in connection with the Mergers in exchange for a stock option to acquire 725,000 shares of Hyperfine common stock for $1.07 per share. F8 · derivative.exercise_date: The shares underlying this option vest and will become exercisable upon the first to occur of the following: (1) the completion of a SPAC transaction within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share of $30.00 or more for at least 20 out of 30 consecutive trading days within four years of the closing of the SPAC transaction; (2) the completion of an IPO within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share that equals or exceeds 3.0 times $3.92 (as adjusted) within four years of the closing of the IPO; or (3) the closing of a private financing round within four years of Mr. Huennekens' start date in which $50 million or more is raised and Hyperfine's stock price per share equals or exceeds 3.0 times $3.92 (as adjusted). Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.